With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.